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Interleukin-27 (IL-27) has been known to exert pleiotropic role in many 
inflammatory-related diseases including parasitic infection. However, its 
involvement during malaria infection has yet to be elucidated. In this study, the role 
and involvement of IL-27 during malaria infection was investigated and the effects 
of modulating its release on the course of the infection, the release of major 
inflammatory cytokines and the histopathological consequences in major affected 
organs during malaria were evaluated.  Plasmodium berghei (P. berghei) ANKA 
infection in male ICR mice was used as a model for malaria infection. The mice 
were inoculated intraperitoneally with 2 x 107 parasite-infected red blood cells 
(PRBCs) whereas the controls received an equivalent dilution of normal RBCs. The 
concentration of IL-27 in the plasma of malarial mice measured by means of ELISA, 
showed persistent elevation of IL-27 right from the early until the late phase of 
infection and its release is independent of the degree of disease severity. The 
modulation of IL-27 release was carried out by treatment of malarial mice with 










antibody (WSX-1 mAb) intravenously. Inhibition of IL-27 with WSX-1 Fc chimera 
and WSX-1 antibodies delayed the appearance of physical signs of illness and 
parasitaemia development and also prolonged the survival of malaria-infected mice. 
Augmentation of IL-27 with rmIL-27 significantly elevated the release of anti-
inflammatory cytokine (IL-10) whereas inhibition and neutralisation of IL-27 with 
WSX-1 Fc chimera and WSX-1 mAb respectively, showed decreased level of IL-10. 
A significant elevation of pro-inflammatory cytokines (IFN-γ and IL-6) was also 
observed, both during augmentation and inhibition of IL-27. From the pattern of 
cytokines release, it can be suggested that IL-27 exerts an anti-inflammatory activity 
in the Th1 type response by signalling the production of IL-10 during malaria. 
Histopathological examination performed on internal organs including the brain, 
lungs, liver, spleen and kidneys of malarial mice showed significant sequestration of 
PRBCs in the microvasculature of all the major organs of malarial mice. Other 
significant histopathological changes were also observed in malarial mice such as 
hyperplasia and hypertrophy of the Kupffer cells in the liver, hyaline membrane 
formation in the lungs, enlargement of the white and red pulp element followed by 
the lost of structure of germinal centre in the spleen, and vacuolation of the kidney 
tubule cells. Treatment with rmIL-27 and WSX-1 Fc chimera failed to show any 
significant improvement on the histopathological conditions of the organs of 
malaria-infected mice. Overall, the results suggest that IL-27 is involved during 
malaria infection and it may play an important anti-inflammatory role during 
immune response against the disease. Modulation of its release produced a positive 
impact on inflammatory cytokine production during the infection, suggesting its 
potential as an immunotherapeutic target in malaria, in which the host may benefit 
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Interleukin-27 (IL-27) telah diketahui mempunyai peranan pleiotropik dalam banyak 
penyakit berkaitan inflamasi termasuk jangkitan parasit. Walau bagaimanapun, 
penglibatannya semasa jangkitan malaria masih belum diperjelaskan. Dalam kajian 
ini, peranan dan penglibatan IL-27 dalam jangkitan malaria telah diselidiki dan 
kesan modulasi penghasilannya ke atas keadaan keseluruhan jangkitan malaria, 
pembebasan sitokin inflamasi utama dan perubahan histopatologi organ-organ utama 
yang terjejas semasa jangkitan malaria telah dinilai. Jangkitan Plasmodium berghei 
(P. berghei) ANKA dalam mencit ICR jantan telah digunakan sebagai model 
jangkitan malaria. Mencit disuntik secara intraperitoneal dengan 2 x 107 sel darah 
merah berparasit. Kepekatan IL-27 dalam plasma mencit yang dijangkiti malaria 
yang diukur melalui kaedah ELISA, menunjukkan peningkatan berterusan IL-27 
bermula dari awal hingga ke akhir fasa jangkitan dan pembebasannya didapati tidak 
bergantung kepada tahap ketenatan jangkitan.  Modulasi ke atas pembebasan IL-27 
dijalankan dengan merawat mencit yang dijangkiti malaria dengan rekombinan 










secara intravena ke atas mencit yang dijangkiti malaria. Perencatan pembebasan IL-
27 oleh WSX-1 Fc chimera dan antibodi WSX-1 memperlahankan kemunculan 
tanda-tanda fizikal jangkitan dan perkembangan parasitemia seterusnya melanjutkan 
tempoh hayat mencit yang dijangkiti malaria. Penambahan IL-27 dengan rmIL-27 
meningkatkan pembebasan sitokin anti-inflamasi (IL-10) secara signifikan manakala 
perencatan dan peneutralan IL-27 masing-masing dengan WSX-1 Fc chimera dan 
antibodi WSX-1, menunjukkan penurunan tahap IL-10. Peningkatan signifikan 
sitokin proinflammasi (IFN-γ dan IL-6) juga diperhatikan semasa penambahan dan 
perencatan IL-27. Daripada corak pembebasan sitokin-sitokin, boleh diusulkan 
bahawa IL-27 menunjukkan aktiviti anti-inflamasi dalam gerakbalas jenis Th1 
dengan mengisyaratkan penghasilan IL-10 semasa malaria. Pemeriksaan 
histopatologi yang dilakukan ke atas organ-organ dalaman termasuk otak, paru-paru, 
hati, limpa dan ginjal menunjukkan sekuestrasi sel-sel darah merah berparasit dalam 
mikrovaskulatur kesemua organ-organ utama mencit yang dijangkiti malaria.   
Perubahan histopatologi lain yang signifikan juga diperhatikan dalam mencit yang 
dijangkiti malaria termasuk hiperplasia dan hipertrofi sel-sel Kupffer dalam hati, 
pembentukan membran hyalin dalam paru-paru, pembesaran elemen pulpa merah 
dan putih diikuti dengan kehilangan struktur pusat germinal dalam limpa, dan 
vakuolasi sel-sel tubul ginjal. Rawatan dengan rmIL-27 dan WSX-1 Fc chimera 
gagal menunjukkan sebarang kesan pembaikan yang signifikan ke atas keadaan 
histopatologi organ-organ mencit yang dijangkiti malaria. Secara keseluruhannya, 
keputusan kajian mencadangkan penglibatan IL-27 semasa jangkitan malaria dan 
ianya mungkin memainkan peranan antiinflamasi yang penting semasa gerakbalas 
imun melawan jangkitan malaria. Modulasi pembebasannya menghasilkan impak 










mencadangkan potensinya sebagai sasaran imunoterapeutik di mana hos boleh 
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